A new paradigm for cancer therapeutics development
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The number of cancer patients has increased due to longer life spans and treatment has become a universal problem. Since molecular-targeted therapies were introduced as a new developmental strategy, certain targets have been examined hundreds of times, with developers overlapping their research efforts. We need to focus our energy and resources on novel drug candidate identification and optimization, in order to enhance the entry of early-stage drug candidates into the therapeutics pipeline. This presents a major opportunity for Korea to jump the decades-old development gap between our programs and those that are more advanced in other countries. Although this country does not have a specific center for validation and development of cancer therapeutics, we do have cutting-edge scientists performing research in many institutions. In this paper, I will review cancer drug development in Korea and suggest future directions, while urging colleagues to utilize their networking expertise so we can move toward a new paradigm of novel therapeutics development. An example of such efforts has begun with the Drug Development Consortium,which was described in the KSBMB chapter. This consortium was launched in 2010 by biochemists, chemists, cell and molecular biologists and pharmacologists. It is clear that effective cancer therapeutics will be developed more efficiently when we all strive for the same goal.
Abstract
The number of cancer patients has increased due to longer life spans and treatment has become a universal problem. Since molecular-targeted therapies were introduced as a new developmental strategy, certain targets have been examined hundreds of times, with developers overlapping their research efforts. We need to focus our energy and resources on novel drug candidate identification and optimization, in order to enhance the entry of early-stage drug candidates into the therapeutics pipeline. This presents a major opportunity for Korea to jump the decades-old development gap between our programs and those that are more advanced in other countries. Although this country does not have a specific center for validation and development of cancer therapeutics, we do have cutting-edge scientists performing research in many institutions. In this paper, I will review cancer drug development in Korea and suggest future directions, while urging colleagues to utilize their networking expertise so we can move toward a new paradigm of novel therapeutics development. An example of such efforts has begun with the Drug Development Consortium,which was described in the KSBMB chapter. This consortium was launched in 2010 by biochemists, chemists, cell and molecular biologists and pharmacologists. It is clear that effective cancer therapeutics will be developed more efficiently when we all strive for the same goal.
참고문헌 (13)
- Slamon, D., "Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials", Semin. Oncol., 28, pp.13~19 (2001)
- Sawyers, C. L., "The cancer biomarker problem", Nature, 452, pp.548~552 (2008)
- Kavallaris, M., "Microtubules and resistance to tubulin-binding agents", Nat. Rev. Cancer, 10, pp.194~204 (2010)
- Fukuyo, Y., "Geldanamycin and its anti-cancer activities", Cancer Lett., 290, pp.24~35 (2010)
- Bates, S. E., "Molecular targets in the National Cancer Institute drug screen", J. Cancer Res. Clin. Oncol., 121, pp.495~500 (1995)
- Smith, S. C., "The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer", Cancer Res., 70, pp.1753~1758 (2010)
- Monga, M., "Developmental therapeutics program at the NCI: molecular target and drug discovery process", Leukemia, 16, pp.520~526 (2002)
- Mi, Q., "Use of the in vivo hollow fiber assay in natural products anticancer drug discovery", J. Nat. Prod., 72, pp.573~580 (2009)
- Martin, V., "Overview of paclitaxel (TAXOL)", Semin. Oncol. Nurs., 9, pp.2~5 (1993)
- Crul, M., "CKD-602. Chong Kun Dang", Curr. Opin. Investig. Drugs, 4, pp.1455~1459 (2003)
- Palazzo, A., "Past, Present and Future of Targeted Therapy in Solid Tumors", Curr. Cancer Drug. Targets., 10, pp.433~461 (2010)
- Drummond, D. C., "Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes", Clin. Cancer Res., 11, pp.3392~3401 (2005)
- Duvic, M., "Vorinostat in cutaneous T-cell lymphoma", Drugs Today (Barc), 43, pp.585~599 (2007)